公开(公告)号：US20160355457A1

公开(公告)日：2016-12-08

申请号：US15164394

申请日：2016-05-25

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Michael Sizensky ,  Harold S. Wilkinson ,  John R. Snoonian ,  Norman Kim ,  Sharon M. Laughlin ,  Roger P. Bakale ,  Kevin Plunkett ,  Patrick Mousaw

IPC: C07C215/64

CPC classification number: C07C215/64 ,  C07B2200/07 ,  C07B2200/13 ,  C07C213/10 ,  C07C2601/14

Abstract: Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Abstract translation: 本文提供了包含可用于治疗，预防和治疗各种病症和疾病的化合物的固体形式。 特别地，本发明提供了包含（ - ） - O-去甲基文拉法辛（包括其盐）的固体形式，其可用于治疗，预防和治疗病症和病症，包括但不限于情感障碍如抑郁症，双相和躁狂症 失调，注意力缺陷障碍，具有多动症的注意力缺陷障碍，帕金森病，癫痫，脑功能障碍，肥胖和体重增加，失禁，痴呆和相关疾病。

公开(公告)号：US20140315910A1

公开(公告)日：2014-10-23

申请号：US14317754

申请日：2014-06-27

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Judy Caron ,  Thomas Wessel ,  Karim LALJI ,  Mark Varney ,  Roger P. Bakale ,  Surendra P. Singh ,  H. Scott Wilkinson ,  Xiping Su ,  Zhengxu Han ,  Stefan G. Koenig

IPC: A61K31/4985 ,  A61K31/135

CPC classification number: A61K31/4985 ,  A61K31/135 ,  C07C211/42 ,  C07C2602/10 ,  A61K2300/00

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract translation: 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂一起可以用于治疗例如更年期，情绪障碍，焦虑障碍或认知障碍。 药物组合物的第一组分是镇静剂佐佐匹克。 药物组合物的第二组分是反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基） 2,3,4-四氢-1-萘胺。 本发明还涉及治疗绝经，围绝经期，情绪障碍，焦虑障碍和认知障碍的方法。

公开(公告)号：US20160016891A1

公开(公告)日：2016-01-21

申请号：US14714892

申请日：2015-05-18

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Hang ZHAO ,  Stefan G. Koenig ,  Charles P. Vandenbossche ,  Surendra Singh ,  Harold Scott Wilkinson ,  Roger P. Bakale

IPC: C07C231/14 ,  C07C231/12 ,  C07C209/62 ,  C07C249/08

CPC classification number: C07C231/14 ,  C07B43/06 ,  C07C209/50 ,  C07C209/62 ,  C07C211/42 ,  C07C231/12 ,  C07C249/08 ,  C07C2602/10

Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.

公开(公告)号：US20140057990A1

公开(公告)日：2014-02-27

申请号：US13956765

申请日：2013-08-01

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Hang Zhao ,  Stefan G. Koenig ,  Charles P. Vandenbossche ,  Surendra Singh ,  Harold Scott Wilkinson ,  Roger P. Bakale

IPC: C07C231/14 ,  C07C209/50 ,  C07C211/42 ,  C07C231/12

CPC classification number: C07C231/14 ,  C07B43/06 ,  C07C209/50 ,  C07C209/62 ,  C07C211/42 ,  C07C231/12 ,  C07C249/08 ,  C07C2602/10

Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.

Abstract translation: 本发明提供了将肟转化成烯酰胺的方便方法。 该方法不需要使用金属试剂。 因此，它产生所需化合物，而不伴随产生大量的金属废物。 酰胺是酰胺和胺的有用前体。 本发明提供了将前手性烯酰胺转化成相应的手性酰胺的方法。 在示例性方法中，通过使用手性氢化催化剂在氢化期间引入手性氨基中心。 在选择的实施方案中，本发明提供了制备包括1,2,3,4-四氢-N-烷基-1-萘胺或1,2,3,4-四氢-1-萘胺亚结构的酰胺和胺的方法。

公开(公告)号：US10011559B2

公开(公告)日：2018-07-03

申请号：US15498726

申请日：2017-04-27

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Hang Zhao ,  Stefan G. Koenig ,  Charles P. Vandenbossche ,  Surendra Singh ,  Harold Scott Wilkinson ,  Roger P. Bakale

IPC: C07C231/14 ,  C07C249/08 ,  C07C209/62 ,  C07C231/12 ,  C07C209/50 ,  C07C211/42 ,  C07B43/06

CPC classification number: C07C231/14 ,  C07B43/06 ,  C07C209/50 ,  C07C209/62 ,  C07C211/42 ,  C07C231/12 ,  C07C249/08 ,  C07C2602/10

Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.